GSK to pay $20M to SEC to resolve bribery charges

U.K. pharmaceutical giant GlaxoSmithKline will pay a civil money penalty in the amount of $20 million to the Securities and Exchange Commission to resolve charges concerning bribery payments made to government officials in China. Jaclyn Jaeger reports.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.